Axsome Therapeutics, Inc. $AXSM Stock Position Raised by Intech Investment Management LLC

Intech Investment Management LLC boosted its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 900.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,751 shares of the company’s stock after purchasing an additional 12,376 shares during the period. Intech Investment Management LLC’s holdings in Axsome Therapeutics were worth $2,536,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Axsome Therapeutics during the 2nd quarter valued at $759,695,000. ABS Investment Management LLC bought a new position in shares of Axsome Therapeutics during the 2nd quarter valued at $171,339,000. Bank of America Corp DE bought a new position in shares of Axsome Therapeutics during the 2nd quarter valued at $110,756,000. First Trust Advisors LP boosted its stake in shares of Axsome Therapeutics by 1,230.2% in the 1st quarter. First Trust Advisors LP now owns 577,479 shares of the company’s stock worth $97,606,000 after buying an additional 534,066 shares during the last quarter. Finally, Pictet Asset Management Holding SA boosted its stake in shares of Axsome Therapeutics by 12.9% in the 3rd quarter. Pictet Asset Management Holding SA now owns 481,524 shares of the company’s stock worth $88,789,000 after buying an additional 54,997 shares during the last quarter. Institutional investors own 81.49% of the company’s stock.

Insider Activity at Axsome Therapeutics

In related news, COO Mark Jacobson sold 10,000 shares of the firm’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total value of $2,086,500.00. Following the transaction, the chief operating officer directly owned 10,000 shares of the company’s stock, valued at approximately $2,086,500. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 20.60% of the stock is owned by company insiders.

Axsome Therapeutics Stock Down 4.7%

Shares of AXSM stock opened at $129.36 on Friday. Axsome Therapeutics, Inc. has a 12 month low of $123.00 and a 12 month high of $260.19. The stock has a market cap of $6.80 billion, a P/E ratio of -42.27 and a beta of 0.86. The company has a current ratio of 1.42, a quick ratio of 1.34 and a debt-to-equity ratio of 1.21. The company has a 50 day simple moving average of $163.75 and a two-hundred day simple moving average of $195.47.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.38. The business had revenue of $259.69 million for the quarter, compared to the consensus estimate of $249.19 million. Axsome Therapeutics had a negative net margin of 18.18% and a negative return on equity of 198.73%. The company’s quarterly revenue was up 51.9% on a year-over-year basis. During the same period last year, the firm earned ($0.94) earnings per share. On average, research analysts expect that Axsome Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on AXSM. Morgan Stanley cut their price objective on Axsome Therapeutics from $249.00 to $223.00 and set an “equal weight” rating for the company in a report on Friday, November 13th. Needham & Company LLC increased their target price on Axsome Therapeutics from $267.00 to $268.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Royal Bank Of Canada lowered their target price on Axsome Therapeutics from $295.00 to $273.00 and set an “outperform” rating on the stock in a report on Tuesday, November 3rd. Piper Sandler dropped their target price on Axsome Therapeutics from $258.00 to $238.00 and set an “overweight” rating on the stock in a research report on Monday, October 26th. Finally, HC Wainwright reissued a “buy” rating on shares of Axsome Therapeutics in a research report on Friday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $266.21.

Read Our Latest Research Report on Axsome Therapeutics

About Axsome Therapeutics

(Free Report)

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

Read More

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.